BidaskClub upgraded shares of Aerie Pharmaceuticals (NASDAQ:AERI) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning.

Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, November 22nd. Canaccord Genuity set a $73.00 target price on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Thursday, November 16th. Cantor Fitzgerald set a $69.00 target price on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Thursday, November 16th. Mizuho restated a buy rating and set a $87.00 target price on shares of Aerie Pharmaceuticals in a research note on Thursday, November 9th. Finally, Guggenheim began coverage on shares of Aerie Pharmaceuticals in a research note on Monday, October 23rd. They set a buy rating and a $80.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $71.43.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at $58.90 on Tuesday. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a one year low of $35.50 and a one year high of $66.60.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP increased its position in shares of Aerie Pharmaceuticals by 31.3% during the 3rd quarter. GSA Capital Partners LLP now owns 6,444 shares of the company’s stock valued at $313,000 after purchasing an additional 1,538 shares during the last quarter. Iguana Healthcare Management LLC increased its position in shares of Aerie Pharmaceuticals by 5.3% during the 3rd quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the company’s stock valued at $4,860,000 after purchasing an additional 5,000 shares during the last quarter. Neuberger Berman Group LLC increased its position in shares of Aerie Pharmaceuticals by 100.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 25,000 shares of the company’s stock valued at $1,215,000 after purchasing an additional 12,500 shares during the last quarter. California Public Employees Retirement System increased its position in shares of Aerie Pharmaceuticals by 47.5% during the 3rd quarter. California Public Employees Retirement System now owns 7,525 shares of the company’s stock valued at $366,000 after purchasing an additional 2,425 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. purchased a new stake in shares of Aerie Pharmaceuticals during the 3rd quarter valued at about $204,000.

ILLEGAL ACTIVITY WARNING: This report was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://theolympiareport.com/2017/12/06/aerie-pharmaceuticals-aeri-upgraded-by-bidaskclub-to-buy.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.